Review





Similar Products

ahr signaling  (MedChemExpress)
98
MedChemExpress ahr signaling
Activation of <t>AHR</t> alleviated fibrotic phenotypes by regulating THE TGF-β1/Smad2/3 signaling pathway. ( A , B ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in TED OFs treated with IAA <t>and</t> <t>CH-223191</t> detected using a western blotting assay ( n = 3 in each group). ( C ) Immunofluorescence assay measured the distribution of AHR in TED OFs ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. ( D , E ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in non-TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( F ) Immunofluorescence assay measured the distribution of AHR in non-TED OFs. ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).
Ahr Signaling, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch+223191/CH-223191/pmc13489212-75-5-18
Average 98 stars, based on 1 article reviews
ahr signaling - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
ahr inhibitor ch223191  (MedChemExpress)
98
MedChemExpress ahr inhibitor ch223191
Activation of <t>AHR</t> alleviated fibrotic phenotypes by regulating THE TGF-β1/Smad2/3 signaling pathway. ( A , B ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in TED OFs treated with IAA <t>and</t> <t>CH-223191</t> detected using a western blotting assay ( n = 3 in each group). ( C ) Immunofluorescence assay measured the distribution of AHR in TED OFs ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. ( D , E ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in non-TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( F ) Immunofluorescence assay measured the distribution of AHR in non-TED OFs. ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).
Ahr Inhibitor Ch223191, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch+223191/CH-223191/pmc13449032-212-1-10
Average 98 stars, based on 1 article reviews
ahr inhibitor ch223191 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
ch 223191  (MedChemExpress)
94
MedChemExpress ch 223191
Activation of <t>AHR</t> alleviated fibrotic phenotypes by regulating THE TGF-β1/Smad2/3 signaling pathway. ( A , B ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in TED OFs treated with IAA <t>and</t> <t>CH-223191</t> detected using a western blotting assay ( n = 3 in each group). ( C ) Immunofluorescence assay measured the distribution of AHR in TED OFs ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. ( D , E ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in non-TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( F ) Immunofluorescence assay measured the distribution of AHR in non-TED OFs. ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).
Ch 223191, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch+223191/Indole/pm42585956-54-26-28
Average 94 stars, based on 1 article reviews
ch 223191 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
ch223191  (MedChemExpress)
98
MedChemExpress ch223191
Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and <t>CH223191</t> treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Ch223191, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch+223191/CH-223191/pmc13453838-60-25-27
Average 98 stars, based on 1 article reviews
ch223191 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
ahr antagonist ch 223191  (MedChemExpress)
98
MedChemExpress ahr antagonist ch 223191
Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and <t>CH223191</t> treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Ahr Antagonist Ch 223191, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch+223191/CH-223191/pmc13397888-65-11-14
Average 98 stars, based on 1 article reviews
ahr antagonist ch 223191 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
organoids  (MedChemExpress)
98
MedChemExpress organoids
Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and <t>CH223191</t> treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Organoids, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch+223191/CH-223191/pm42436183-371-29-43
Average 98 stars, based on 1 article reviews
organoids - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier

Image Search Results


Activation of AHR alleviated fibrotic phenotypes by regulating THE TGF-β1/Smad2/3 signaling pathway. ( A , B ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( C ) Immunofluorescence assay measured the distribution of AHR in TED OFs ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. ( D , E ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in non-TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( F ) Immunofluorescence assay measured the distribution of AHR in non-TED OFs. ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).

Journal: Investigative Ophthalmology & Visual Science

Article Title: Gut Microbial Metabolite Indole-3-Acetic Acid Exerts Protective Effects by Regulating Orbital Fibroblast Fibrosis in Thyroid Eye Disease

doi: 10.1167/iovs.67.10.35

Figure Lengend Snippet: Activation of AHR alleviated fibrotic phenotypes by regulating THE TGF-β1/Smad2/3 signaling pathway. ( A , B ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( C ) Immunofluorescence assay measured the distribution of AHR in TED OFs ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. ( D , E ) Protein expression of fibronectin, collagen Iα1, α-SMA, AHR, and CYP1A1, and the phosphorylation of Smad2 and Smad3 in non-TED OFs treated with IAA and CH-223191 detected using a western blotting assay ( n = 3 in each group). ( F ) Immunofluorescence assay measured the distribution of AHR in non-TED OFs. ( n = 3 in each group). Blue represents DAPI, and red represents AHR. Scale bar : 20 µm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).

Article Snippet: To evaluate the role of AHR signaling in OF activation, cells were pretreated with 10-μM AHR antagonist CH-223191 (MedChemExpress) for 2 hours before stimulation with TGF-β1 and IAA.

Techniques: Activation Assay, Expressing, Phospho-proteomics, Western Blot, Immunofluorescence

IAA attenuated cell migration by activating AHR in OFs. ( A – D ) TED OFs ( A , B ) and non-TED OFs ( C , D ) were treated with TGF-β1, IAA, and the AHR antagonist CH-223191 for 24 or 48 hours. Cell migration was examined using a scratch wound healing assay ( n = 3 in each group). Scale bar : 100 µm. * P < 0.05, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).

Journal: Investigative Ophthalmology & Visual Science

Article Title: Gut Microbial Metabolite Indole-3-Acetic Acid Exerts Protective Effects by Regulating Orbital Fibroblast Fibrosis in Thyroid Eye Disease

doi: 10.1167/iovs.67.10.35

Figure Lengend Snippet: IAA attenuated cell migration by activating AHR in OFs. ( A – D ) TED OFs ( A , B ) and non-TED OFs ( C , D ) were treated with TGF-β1, IAA, and the AHR antagonist CH-223191 for 24 or 48 hours. Cell migration was examined using a scratch wound healing assay ( n = 3 in each group). Scale bar : 100 µm. * P < 0.05, *** P < 0.001, **** P < 0.0001 compared to the TGF-β1 group (one-way ANOVA).

Article Snippet: To evaluate the role of AHR signaling in OF activation, cells were pretreated with 10-μM AHR antagonist CH-223191 (MedChemExpress) for 2 hours before stimulation with TGF-β1 and IAA.

Techniques: Migration, Wound Healing Assay

Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Journal of Advanced Research

Article Title: The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma

doi: 10.1016/j.jare.2025.10.079

Figure Lengend Snippet: Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: 2 μM Benzo[a]pyrene (B1760; Merck) and 100 μM kynurenine (HY-104026; MedChemExpress) were used as AhR agonists to activate the AhR signaling pathway, while 20 μM CH223191 (HY-12684; MedChemExpress) and 20 μM resveratrol (HY-16561; MedChemExpress) were employed as AhR antagonists to inhibit the pathway.

Techniques: Staining, Immunohistochemistry